Navigation Links
Early Results of the CellCept Spare the Nephron Study Examine,Kidney Function

SAN FRANCISCO, May 07, 2007 /PRNewswire/ -- Interim results from a multicenter trial investigating a novel kidney-sparing treatment protocol using CellCept(R) (mycophenolate mofetil) were presented at the American Transplant Congress. This and other Spare the Nephron (STN) trials in kidney and liver transplant recipients examine ways to prevent rejection without damaging kidneys.

As transplant patients are living longer, doctors are finding that older therapies such as steroids and calcineurin inhibitors (CNIs) can cause impairment of kidney function and damage to the blood vessels and filtering capacity of the kidneys.(1)(2) The STN trials are being conducted at more than 35 transplant centers in the United States and Canada and use CellCept and other immunosuppressants in combinations that reduce or eliminate the use of steroids and CNIs.

"Our goal for the Spare the Nephron trial in kidney transplant recipients is to determine the safest and most effective immunosuppressive therapy regimen that avoids the nephrotoxic effects of CNIs while preventing rejection," said Matthew Weir, M.D., professor and director of the division of nephrology at the University of Maryland School of Medicine. "The preliminary study results are very encouraging."

Dr. Weir reported that first-year results in kidney transplant recipients demonstrated that patients on CellCept and sirolimus maintenance therapy showed improvements in glomerular filtration rate (GFR) of their kidneys without increasing rejection rates.

A total of 208 of 305 kidney transplant patients completed 12 months of follow-up in this open-label, prospective, randomized, multicenter study. Patients initially treated with CellCept and a CNI were randomized to receive CellCept and sirolimus or to continue their current treatment regimen of CellCept and a CNI. Efficacy endpoints included the proportions of patients experiencing acute reject
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
2. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
3. Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen
4. Promising Data on Cognitive Effects of Safinamide in Early Parkinsons Disease
5. Dasatinib Shows High Early Response Rate as First Treatment for Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report
6. Clinical Trial Excellence: Shaping Markets Through Early Communication of Clinical Trial Data
7. Separate Sets of Research Show Treatment Improved Quality of Life in as Early as Three Weeks; Patient Adherence to Medication is Multifactorial
8. Studies Presented at Neurology Conference Highlight Early Efficacy, Long-Term Tolerability, and High Patient Satisfaction with Betaseron
9. Immediate Treatment of Early MS Patients with Betaferon Significantly Delayed Permanent Disability
10. First of Its Kind Data Show: Immediate Treatment of Early MS Patients with Betaseron Significantly Delayed Permanent Disability
11. Newly Published Study Reveals Femara Improves Chances for Harder to Treat Early Breast Cancer Relapse in Postmenopausal Women
Post Your Comments:
(Date:8/19/2014)... , Aug. 19, 2014  AVIA – a ... task on the biggest problems in healthcare ­– announces ... Northern California , as the most recent addition ... Health will participate in AVIA,s inaugural cohort focused helping ... care and transparency among a patient,s providers so they ...
(Date:8/19/2014)... Calif. , Aug. 19, 2014  Cardiva Medical, ... two tranches of a $16.5 million Series 3 private ... with GE Capital. The Company will use the proceeds ... facility to expand commercial efforts for its VASCADE® Vascular ... . Investing in Series 3 private ...
(Date:8/19/2014)... , Aug. 19, 2014 ... Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), today ... Annual Meeting of the American Academy of ... Care Surgery in Philadelphia, Pennsylvania ... The presentation will report results from a recently ...
Breaking Medicine Technology:AVIA and Sutter Health Join Forces to Address Healthcare's Most Pressing Challenges 2Cardiva Medical, Inc. Announces Completion of the first two tranches of Series 3 Private Equity Financing and the Closing of a Senior Secured Debt Facility with GE Capital 2Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 2Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 3
... NEW YORK, Oct. 31 A recent outbreak ... to,as "the superbug," should cause organizations and facilities ... The superbug is resistant to common antibiotics. ... abscesses, boils and other pus-filled,lesions. Superbug infections prior ...
... Oct. 31 United,Therapeutics Corporation (Nasdaq: UTHR ... today that they will release the results of ... formulation of treprostinil,in pulmonary arterial hypertension (PAH) before ... Therapeutics will expand its previously scheduled conference,call on ...
Cached Medicine Technology:'Superbug' Outbreak Calls for Immediate Increased Attention on Infection Control 2Results of TRIUMPH-1 Trial of Viveta in Pulmonary Arterial Hypertension to Be Announced Before Market Open on Thursday, November 1, 2007 2
(Date:8/20/2014)... IQ Formulations , a top national health ... Inc. 500 , distinguishing it as one of the fastest ... only made the list, but was ranked in the top ... three years. It also ranked ninth among all health companies, ... second fastest growing company in the Miami metro area. ...
(Date:8/20/2014)... BCC Research ( http://www.bccresearch.com ) ... AND DETECTORS: TECHNOLOGIES AND GLOBAL MARKETS , the ... to grow to $15.2 billion by 2019, with ... 15.9%. Increasing industrialization is driving significant growth ... expanding range of industrial applications such as military ...
(Date:8/20/2014)... 2014 It’s no secret that millions ... the National Institute on Drug Abuse, nearly 24 million ... even more alarming is the fact that the total ... , Those locked in a struggle with substance abuse ... But now, the newly-redesigned AbuseTreatmentCenters.net has released updated lists ...
(Date:8/20/2014)... York, NY (PRWEB) August 20, 2014 ... Awards. PM360, a leading health-marketing industry trade magazine, will ... 2009, the Trailblazer Awards are given to outstanding companies, ... has to offer. , “We are proud to ... our call to entries with double the number of ...
(Date:8/20/2014)... York, NY (PRWEB) August 20, 2014 ... world’s largest nutrition school, is proud to announce ... Integral Studies (CIIS), a cutting-edge university offering ... Nutrition’s Health Coach Training Program are now eligible ... of Arts in Integrative Health Studies. , “I’m ...
Breaking Medicine News(10 mins):Health News:Leading Health Supplement Company IQ Formulations Among Inc. Magazine’s Top 50 Fastest Growing Private Companies in the United States 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 3Health News:Re-Launched AbuseTreatmentCenters.net Offering New List of Substance Abuse Resources 2Health News:PM360 Announces 2014 Trailblazer Award Finalists 2Health News:PM360 Announces 2014 Trailblazer Award Finalists 3Health News:PM360 Announces 2014 Trailblazer Award Finalists 4Health News:PM360 Announces 2014 Trailblazer Award Finalists 5Health News:PM360 Announces 2014 Trailblazer Award Finalists 6Health News:PM360 Announces 2014 Trailblazer Award Finalists 7Health News:PM360 Announces 2014 Trailblazer Award Finalists 8Health News:Integrative Nutrition Announces New Partnership with California Institute of Integral Studies 2Health News:Integrative Nutrition Announces New Partnership with California Institute of Integral Studies 3
... cohort studies on the association of alcohol consumption with colorectal ... 2 from Australia, 13 from Western Europe, and 24 from ... least at higher levels of consumption, is associated with an ... was no increase in the risk for consumers reporting an ...
... , TUESDAY, Sept. 13 (HealthDay News) --The lifestyle changes ... disease may also improve sexual function in men with ... from the Mayo Clinic in Rochester, Minn., analyzed six ... determine how lifestyle changes and drugs used to treat ...
... for an effective vaccine and treatment against the potentially fatal ... the discovery of two ,Achilles, heels, within the virus. ... South Wales (UNSW) studied individuals at high risk of HCV ... the onset of infection. Using a new technique ...
... Canadian researchers has found the first evidence that lifelong ... While hearing studies have already shown that trained musicians ... is the first study to examine hearing abilities in ... 18 to 91 years of age. The study ...
... HealthDay Reporter , MONDAY, Sept. 12 (HealthDay News) -- ... become fathers, perhaps because they don,t need to compete with ... with their children. The findings don,t prove that fatherhood ... hormonal systems in men may detect that they,ve become fathers ...
... MONDAY, Sept. 12 (HealthDay News) -- Implantable electronic devices ... heart conditions and save lives, but these benefits may ... complications, a new study suggests. Researchers from the ... that people who develop an infection related to a ...
Cached Medicine News:Health News:Relation of alcohol consumption to colorectal cancer 2Health News:Breakthrough opens new avenues for hep C vaccine 2Health News:Science finding is music to the ears 2Health News:Testosterone Levels Seem to Fall With Fatherhood 2Health News:Testosterone Levels Seem to Fall With Fatherhood 3Health News:Heart Devices Like Pacemakers Linked to Infections 2
Inquire...
Superior Skin Care...Convex FlexWear skin barrier is secure and provides extended weartime. Security and confidence assured with internal non-reflux valves and a drain valve that allows regulation of...
Protects skin from corrosive drainage with the standard wear, FlexWear skin barrier. Security and confidence assured with porous tape, internal non-reflux valves, convenient drain valve....
Firstchoice drainable pouch with softflex skin barrier, cushionfit backing, transparent odor-barrier quiet film and microporous adhesive....
Medicine Products: